23794-15-2

Basic information

• Product Name: 1-(2-CHLORO-PYRIDIN-4-YL)-ETHANONE
• Synonyms: 1-(2-chloro-4-pyridinyl)ethanone(SALTDATA: FREE);Ethanone, 1-(2-chloro-4-pyridinyl)-;1-(2-Chloro-4-pyridinyl)ethanone;1-(2-Chloro-4-pyridyl)ethanone;4-ACETYL-2-CHLOROPYRIDINE;1-(2-CHLORO-PYRIDIN-4-YL)-ETHANONE;1-(2-chloro-4-pyridinyl)-1-ethanone;1-(2-Chloropyridin-4-yl)ethan-1-one
• CAS NO: 23794-15-2
• Molecular Formula: C₇H₆ClNO
• Molecular Weight: 155.58
• Product Categories: Pyridine series;Pyridines
• Mol File: 23794-15-2.mol
• Article Data: 24

Chemical Properties

• Melting Point: 36.5 °C
• Boiling Point: 270.16 °C at 760 mmHg
• Flash Point: >110℃
• Appearance: /
• Density: 1.233 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.535
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: -1.55±0.10(Predicted)
• CAS DataBase Reference: 1-(2-CHLORO-PYRIDIN-4-YL)-ETHANONE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-CHLORO-PYRIDIN-4-YL)-ETHANONE(23794-15-2)
• EPA Substance Registry System: 1-(2-CHLORO-PYRIDIN-4-YL)-ETHANONE(23794-15-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• RIDADR: UN2811
• WGK Germany: 3
• HazardClass: IRRITANT-HARMFUL
• Hazardous Substances Data: 23794-15-2(Hazardous Substances Data)

Usage

Uses

1-(2-Chloro-4-pyridinyl)ethanone is used for the synthesis of pyrimidine derivatives as hSMG-1 inhibitors in the treatment of cancer.

InChI:InChI=1/C7H6ClNO/c1-5(10)6-2-3-9-7(8)4-6/h2-4H,1H3

Upstream product

• 33252-30-1 2-chloro-4-pyridinenitrile 
• 917-64-6 methyl magnesium iodide 
• 14432-12-3 4-Amino-2-chloropyridine 
• 431-03-8 dimethylglyoxal 
• 65287-34-5 2-chloropyridine-4-carbonyl chloride 
• 6313-54-8 2-chloroisonicotinic acid, 
• 2402-96-2 4-acetylpyridine N-oxide 
• 7646-93-7 potassium hydrogensulfate 
• 250263-39-9 2-chloro-4-(N-methyl-N-methoxycarbamoyl)pyridine 
• 861417-45-0 3-(2-chloro-4-pyridyl)-3-oxo ethyl propanoate 
• 75-16-1 methylmagnesium bromide 
• 917-54-4 methyllithium 

Downstream Products

• 1307255-24-8 2-chloro-4-(1-fluoroethyl)pyridine 
• 521092-52-4 C₁₈H₂₂ClFN₂O₂ 
• 521092-30-8 5-(2-chloropyridin-4-yl)-1-(4-fluorophenyl)-4-imidazolin-2-one 

Relevant articles and documents

Pyrrolopyridine inhibitors of mitogen-activated protein kinase-activated protein kinase 2 (MK-2)

A new class of potent kinase inhibitors selective for mitogen-activated protein kinase-activated protein kinase 2 (MAPKAP-K2 or MK-2) for the treatment of rheumatoid arthritis has been prepared and evaluated. These inhibitors have IC50 values as low as 10 nM against the target and have good selectivity profiles against a number of kinases including CDK2, ERK, JNK, and p38. These MK-2 inhibitors have been shown to suppress TNFα production in U397 cells and to be efficacious in an acute inflammation model. The structure-activity relationships of this series, the selectivity for MK-2 and their activity in both in vitro and in vivo models are discussed. The observed selectivity is discussed with the aid of an MK-2/inhibitor crystal structure.

Casein kinase 1 (CK1) inhibitor for plants (by machine translation)

[Problem] to provide various lead compounds PHA derivatives, and/or circadian rhythm control agent having stronger CK1 inhibitor activity. [Solution] a compound represented by formula I, or a salt thereof or a solvate thereof. (R1 The, H or C1 - 5 A straight-chain, branched or cyclic alkyl group, alkenyl group or alkynyl group, R2 The, H, halogen (F, Cl, Br or I), or a C1 - 4 The alkyl group, the ring A, 5 - 8 membered lactam ring showing; however, R1 And R2 Except H together. )[Drawing] no (by machine translation)

Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors

The Rho kinases (ROCK1 and ROCK2) are highly homologous serine/threonine kinases that act on substrates associated with cellular motility, morphology, and contraction and are of therapeutic interest in diseases associated with cellular migration and contraction, such as hypertension, glaucoma, and erectile dysfunction. Beginning with compound 4, an inhibitor of ROCK1 identified through high-throughput screening, systematic exploration of SAR, and application of structure-based design, led to potent and selective ROCK inhibitors. Compound 37 represents significant improvements in inhibition potency, kinase selectivity, and CYP inhibition and possesses pharmacokinetics suitable for in vivo experimentation.